Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.Tokyo, Japan, July 4, 2006 - (JCN JCN - Jane's Combat Network JCN - Japan Corporate News JCN - Jewish Congregational Network JCN - Job Control Number JCN - joint communications network (US DoD) JCN - Journal of Cardiovascular Nursing JCN - Journal of Child Neurology JCN - Journal of Christian Nursing JCN - Journal of Cognitive Neuroscience JCN - Journal on Communications Networks (IEEE Communications Society) Newswire) - Eisai Co., Ltd. (TSE: 4523) has established a new pharmaceutical marketing subsidiary in Singapore Singapore (sĭng`gəpôr, sĭng`ə–, sĭng'gəpôr`), officially Republic of Singapore, republic (2005 est. pop. 4,426,000), 240 sq mi (625 sq km). It consists of the island of Singapore (210 sq mi/544 sq km) and about 60 small adjacent islands at the southern tip of the Malay Peninsula, SE Asia., "Eisai (Singapore) Pte., Ltd." (ESN ESN - Educationally Sub-Normal (UK) ESN - Electrical Symbol Number ESN - Electronic Serial Number ESN - Electronic Signage Network ESN - Electronic Sports Network ESN - Electronic Switched Network ESN - Elysian Space Navy (Honor Harrington science fiction novels) ESN - Emergency Service Number ESN - Energy Sciences Network (Sprint) ESN - English-Speaking Nation ESN - Enterprise Storage Network ESN - EOSDIS Science Network), which has launched pharmaceutical import and marketing business. Previously, Eisai's pharmaceutical import and marketing business in Singapore was handled by Eisai Asia Regional Services Pte. Ltd. (EARS; Head office: Singapore; President: Hiroshi Kimura), but EARS has recently transferred this business to ESN. By launching operations with this new company, Eisai aims to strengthen its pharmaceutical business in Singapore and further contribute to patients' value in the region. EARS will renew its operation as a holding company assuming specific function of the seven local subsidiaries in the Asian region, including this newly established ESN in Singapore and existing six others in China, Thailand, Malaysia, the Philippines, Hong Kong and India. Profile of Eisai (Singapore) Pte. Ltd. Capital: 300,000 Singapore dollars (approx. 22,000,000 yen) Location: Singapore President: Celine Ting Scope of Business: Import, marketing, and promotion of pharmaceuticals Capital Alliance: 100% subsidiary of EARS About Eisai Co., Ltd. Eisai Co., Ltd. (TSE: 4523)(OTC: ESALY) is a research-based human health care company that discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai employs more than 8,000 people worldwide. For more information, please visit http://www.eisai.co.jp. Source: Eisai Co., Ltd. Contact: Eisai Co., Ltd. Corporate Communications Department +81-3-3817-5120 Copyright [c] 2006 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion